Autologous mesenchymal stromal cells reduced relapses in pediatric steroid-dependent nephrotic syndrome
Severe steroid-dependent nephrotic syndrome can trap children and young adults in a cycle of repeated relapses, prolonged immunosuppression, and cumulative glucocorticoid toxicity. In this phase I open-label study, autologous bone marrow–derived mesenchymal stromal cells were infused as a steroid-sparing strategy in a small cohort with difficult-to-control idiopathic nephrotic syndrome, and the signal was strongest in children.
The trial enrolled 16 patients, including 10 children and 6 adults. After autologous bone marrow–derived mesenchymal stromal cells were prepared and infused, oral immunosuppression was tapered and participants were followed for 12 months for safety, efficacy, and immunomodulatory changes in vivo. Safety was the first question, and it was answered cautiously but favorably: adverse events were limited and not related to the cell infusions.
All patients relapsed during follow-up.
Pediatric benefit emerged against a background of persistent disease activity
The broader cohort did not show disease quiescence, which is important because the trial was not testing a curative intervention. It was testing whether cell therapy could reduce the frequency and timing of relapse while allowing less prednisone exposure. In the 10 treated children, the time to first relapse was delayed compared with the previous 12 months, and the number of relapses fell during the year after infusion. The reduction in relapses reached statistical significance, with the clearest treatment effect concentrated in the pediatric subgroup.
This pattern fits the biology of nephrotic syndrome in a way that simple symptom counting does not fully capture. Relapsing nephrotic syndrome reflects an immune process that can return even after temporary clinical control, and the proposed value of mesenchymal stromal cells lies in their immunomodulatory behavior rather than direct renal replacement. By shifting immune signaling, these cells may dampen the inflammatory and lymphocyte-driven forces that destabilize podocyte function and drive proteinuria.
The adults did not share the same benefit. No treatment effect was observed in the adult subgroup, which makes the pediatric response all the more striking and raises the possibility that age, disease chronicity, immune architecture, or prior treatment burden influenced responsiveness. The study was not designed to dissect those differences, but the split between children and adults is clinically meaningful and should not be blurred by cohort averages.
Prednisone exposure fell as relapse control improved
A major practical goal in steroid-dependent nephrotic syndrome is to lower the lifetime burden of glucocorticoids without losing remission control. In the children, cumulative prednisone dose was reduced at 12 months compared with baseline. That change matters at the bedside because the harms of prolonged corticosteroid exposure are not abstract: growth suppression, metabolic effects, mood and sleep disturbance, bone toxicity, and infection risk all accumulate as the doses climb and the relapses repeat.
The study also tracked immunosuppressive drug use, and the figure data show fewer immunosuppressive drugs needed to maintain remission after treatment, again with the clearest effect in children. The intervention did not eliminate the need for ongoing disease management, but it did appear to ease the treatment burden in a population in which every additional drug can widen the safety margin in one direction while narrowing it in another.
Immune cell shifts tracked with the clinical response
The most interesting mechanistic signal came from the immunologic assays performed in the pediatric group. Clinical benefit was mirrored by a reduction in total CD19+ B cells, mature B cells, and memory B cells, alongside an increase in regulatory T cells. Those changes persisted in vivo for roughly 3 to 6 months after infusion.
That timing is biologically plausible. Mesenchymal stromal cells are known for immunoregulatory effects rather than direct cytotoxicity, and the observed expansion of regulatory T cells together with contraction of B-cell populations suggests a temporary rebalancing of the immune system toward a less relapse-prone state. In a disorder where immune dysregulation appears to drive glomerular permeability, a shift away from active B-cell and effector signaling offers a coherent explanation for the delayed relapse pattern.
The durability of that signal is the central issue. The immunomodulatory effect peaked in a window of months rather than years, and the authors interpret those data as support for repeating MSC infusions at 3 to 6 months if the goal is to sustain benefit. That inference is restrained, but it is also clinically reasonable: a therapy that resets immune balance for part of a year may need re-dosing if the underlying disease biology reasserts itself.
A phase I result that supports feasibility, not routine use
This was a phase I study, so the most defensible conclusion is about feasibility and early safety, not practice change. Autologous bone marrow–derived mesenchymal stromal cells were successfully prepared and administered, and the infusion strategy did not produce infusion-related toxicity in this small cohort. For families facing severe steroid-dependent disease, that safety signal matters because experimental therapies in pediatrics must clear a high bar before any efficacy discussion becomes clinically relevant.
The trial also has obvious limits. The sample was small, the study was open-label, all patients relapsed at some point during follow-up, and the adult subgroup did not benefit. The comparison against the prior 12 months strengthens the pediatric signal, but it cannot substitute for a blinded randomized trial with a larger sample and a prespecified strategy for repeat dosing. The study also leaves open whether repeated infusions would extend the immunologic effect, reduce relapse burden more durably, or simply reproduce a transient response.
Even so, the clinical logic is straightforward. A cell therapy that can reduce relapse frequency, delay recurrence, lower prednisone exposure, and modulate B-cell and regulatory T-cell compartments in children with severe steroid-dependent nephrotic syndrome deserves further testing. The next step is not to assume efficacy in routine care, but to determine whether a repeat-infusion schedule can preserve the pediatric benefit without eroding the favorable safety profile seen in this first-in-human setting.
Trial registration: EudraCT 2016-004804-77.